Received Feb 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | — | — |
Late second dose; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a male patient who received Herpes zoster (Shingles vaccine) for prophylaxis. Previously administered products included Varicella zoster vaccine (Patient received first dose in April 2024). On 04-FEB-2025, the patient received the 2nd dose of Shingles vaccine. On 04-FEB-2025, an unknown time after receiving Shingles vaccine, the patient experienced drug dose administration interval too long (Verbatim: Late second dose). The outcome of the drug dose administration interval too long was unknown. Additional Information: GSK Receipt Date: 05-FEB-2025 Patient reported about the shingles vaccine, stated that he had second one, and the pharmacy told him that it was ok, as patient received first one on Apr 2024, but he was not able to get 2nd one until the day before reporting, so it was longer than 6 months. The patient received 2nd dose of Shingles vaccine, later than the recommended interval, which led to lengthening of vaccinations schedule.